Reuters logo
BRIEF-Cerenis Therapeutics announces top line results of CARAT Phase II study
March 1, 2017 / 4:35 PM / 9 months ago

BRIEF-Cerenis Therapeutics announces top line results of CARAT Phase II study

March 1 (Reuters) - Cerenis Therapeutics Holding SA:

* Cerenis Therapeutics announces top line results of CARAT phase II study

* Findings show no statistical difference between CER-001 and placebo in study`s primary endpoint of percentage change from baseline in percent atheroma volume Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below